Name: HYPP Hyperkalemic Periodic Paralysis
Brand: Equigerminal
Price: 329.0 DKK

Product form

HYPP Hyperkalemic Periodic Paralysis

DNA test for the Hyperkalemic Periodic Paralysis Disease (HYPP). This DNA test verifies the presence of the recessive HYPP gene. Sample requirements 30...

329,00 kr Incl. VAT

About

This DNA test verifies the presence of the Hyperkalemic Periodic Paralysis (HYPP) genetic variant.

Why test?

This genetic test helps breeders identify horses carrying the HYPP genetic variant, allowing informed breeding decisions and helping prevent the birth of affected foals.

All descendants of Impressive should be tested for HYPP.

Because HYPP is a dominant disorder, the mutation may also occur in other horse breeds through crossbreeding.

Testing is also recommended for horses showing clinical signs compatible with HYPP.

Results

The DNA test verifies the presence of the recessive HYPP gene and presents results as one of the following:

N/ – Normal - Absence of the allele responsible for HYPP.
N/H – Affected - Positive heterozygous for HYPP. Presence of one copy of the allele responsible for HYPP. The horse is affected with the HYPP disorder and there is a 50% chance this horse will pass a HYPP allele to its offspring.
H/ – Affected- Positive homozygous for HYPP. Presence of two copies of the allele responsible for HYPP. The horse is affected with the HYPP disorder and there is a 100% chance this horse will pass a HYPP allele to its offspring.

Sample

30 to 40 hair roots or 5 mL of blood in K3 EDTA tube

Send your sample by regular mail or express delivery to:

Equigerminal Lab HIESE
Rua da Quinta do Sobreiro Nº25
3230-343 Penela, Portugal

Turnaround

2 to 5 working days

How it works

🛒 Purchase the test: select and buy the test online.

📧 Receive instructions: after payment confirmation you receive sample collection instructions by e-mail.

✨ Collect the sample yourself: pull 20 to 40 hair roots with the bulb attached, or ask your veterinarian to collect blood in a K3-EDTA tube.

📄 Complete the form: print and complete the submission form with the animal identification.

📮 Send it to the laboratory: Equigerminal, S.A., HIESE, Rua da Quinta do Sobreiro, 25, Quinta Vale do Espinhal, 3230-343 Penela, PORTUGAL.

📄 Receive your report: your certified report is issued as soon as the analysis is validated.

FAQs

Which samples can be submitted?

The test can be performed using 30–40 hair roots or 5 mL of blood collected in a K3 EDTA tube.

Which horses should be tested?

Testing is recommended for all descendants of Impressive, horses intended for breeding, and horses showing clinical signs compatible with HYPP.

What do the results mean?

N/N: Horse is free of the HYPP mutation.
N/H: Horse is affected and has a 50% chance of passing the mutation to its offspring.
H/H: Horse is affected and will pass the mutation to all offspring.

Is HYPP a recessive disorder?

No. Although the original text incorrectly refers to a recessive gene in some places, HYPP is a dominant genetic disorder. Both N/H and H/H horses are affected, while only N/N horses are unaffected.

How long does it take to receive the results?

Results are available within 2 to 5 working days after sample arrival at the laboratory.

More

Hyperkalemic Periodic Paralysis (HYPP) is an inherited muscle disorder caused by a mutation in the sodium channel gene.

The defective sodium channels become "leaky," making skeletal muscle excessively excitable and causing involuntary muscle contractions.

Clinical episodes are triggered when blood potassium levels fluctuate, particularly after fasting followed by consumption of high-potassium feeds such as alfalfa.

Affected horses may experience episodes ranging from mild muscle tremors to collapse or sudden death due to respiratory failure or cardiac arrest.

HYPP has been identified in descendants of the American Quarter Horse stallion Impressive.

HYPP is a dominant disorder, meaning both heterozygous (N/H) and homozygous (H/H) horses are affected. Only horses with the N/N genotype are free of the disorder.